Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, \> 40 years of age~2. Clinical diagnosis of moderate to severe COPD as defined by the GOLD criteria:~   Post-bronchodilator FEV1/FVC \< 70% Post-bronchodilator FEV1 \< 70% predicted~3. Cigarette consumption of 10 pack-years or more. Patients may be active smokers.~4. The presence of chronic cough and sputum production~5. Willingness to make return visits and telephone availability for the study duration~Exclusion Criteria:~1. A diagnosis of asthma as established by the study investigator on the basis of the recent American Thoracic Society/European Respiratory Society guidelines~2. Clinically significant bronchiectasis~3. Oxygen use \>12 hours/day~4. Known sensitivity to roflumilast~5. Use of other methylxanthines within 1 month (theophylline)~6. Changes to current maintenance COPD therapy within one month~7. Pregnancy~8. An acute illness requiring antibiotics and/or corticosteroids within the month prior to enrolment.~9. Immunosuppression~   1. HIV~  2. Solid organ transplant~  3. Active malignancy~  4. Systemic corticosteroid use ≥ prednisone 20mg / day~  5. Other immunosuppressants~10. Terminal illness defined as anticipated survival \<12 months~11. Severe comorbidities including uncontrolled angina, congestive heart failure, end-stage renal disease, liver failure, or other conditions that would preclude the patient from safely completing the required tests or the study.~    -

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient.
- Daliresp (Type: ACTIVE_COMPARATOR): The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models

Based on this trial design, predict the completion outcome and termination type (if applicable).